Press Releases

RANCHO CUCAMONGA, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2017, ended June 30, 2017, after the market closes on Wednesday, August 9, 2017, and will hold a conference call to

RANCHO CUCAMONGA, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that a federal jury delivered a unanimous verdict in favor of Amphastar in a lawsuit brought by Momenta Pharmaceuticals, Inc. and Sandoz Inc. (the "Plaintiffs") in the U.S.

RANCHO CUCAMONGA, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President, will be presenting at the Jefferies Global Healthcare Conference on Tuesday, June 6, 2017 at 10:00 a.m. Eastern Time in New York, NY.

RANCHO CUCAMONGA, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 20 th Annual Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16, 2017 at 5:00 p.m.

Reports Net Revenues of $56.7 Million for the Three Months Ended March 31, 2017

RANCHO CUCAMONGA, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2017 ended March 31, 2017, after the market closes on Monday, May 8 th , 2017, and will hold a conference call to discuss

RANCHO CUCAMONGA, Calif., March 31, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 16 th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 12:50 p.m. Eastern Time in New York, NY.

Reports Net Revenues of $63.5 Million for the Three Months Ended December 31, 2016

RANCHO CUCAMONGA, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2016 ended December 31, 2016, after the market closes on Monday, March 13 th , 2017, and will hold a conference call

RANCHO CUCAMONGA, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced today that the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") for its New Drug Application ("NDA") for Naloxone Hydrochloride 2mg/0.5mL Nasal